Trial | NCT02022228  Report issue

Title

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    200
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.
Study Started
Jul 31
2012
Primary Completion
Dec 31
2015
Anticipated
Study Completion
Jun 30
2016
Anticipated
Last Update
Dec 27
2013
Estimate

Drug triptorelin

0.2 mg triptorelin, ih

  • Other names: triptorelin: Diphereline

Drug hCG

1000 IU hCG, im

Drug hCG

500IU hCG, im

0.2mg triptorelin and 500 IU hCG Experimental

Patients were triggered with 0.2mg triptorelin and 500 IU hCG

0.2mg triptorelin and 1000 IU hCG Experimental

Patients were triggered with 0.2mg triptorelin and 1000 IU hCG

Criteria 

Inclusion Criteria:

patients with polycystic ovarian syndrome
patients with polycystic ovarian morphology on ultrasound
patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins

Exclusion Criteria:

patients undergoing coasting
patients with past ovarian surgery
No Results Posted